nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2026, 19, v.67 2063-2067
癌毒病机理论视角下结直肠癌消皮素D介导焦亡微环境失衡的病机阐释及辨治思路
基金项目(Foundation): 国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202208);国家中医药管理局高水平中医药重点学科建设项目(国中医药人教函[2023]85号); 江苏省教育厅江苏高校优势学科建设工程项目
邮箱(Email): hbcheng@njucm.edu.cn;
DOI: 10.13288/j.11-2166/r.2026.19.006
发布时间: 2026-09-29
出版时间: 2026-09-29
移动端阅读
摘要:

基于癌毒病机理论,认为癌毒贯穿结直肠癌病程始终,脾气亏虚为发病之本,湿热瘀毒为病机演变之要,并进一步探讨其与“炎症小体预激活-反复活化-消皮素D介导的焦亡微环境失衡”现代病理过程的内在联系,认为脾气亏虚是炎症小体预激活的上游病理基础,湿热瘀毒是炎症小体反复活化及消皮素D介导的焦亡炎症放大和微环境持续失衡的关键驱动因素,二者先后相因、相兼为患,共同推动早期结直肠癌发生发展。以抗癌解毒为纲,在健脾益气与清化湿热、化瘀解毒并举的中医辨治思路基础上,进一步阐明相关治法干预结直肠癌消皮素D介导的焦亡微环境失衡的现代机制内涵,以期为结直肠癌癌毒病机理论的现代科学阐释及临床辨治提供理论依据。

Abstract:

Based on the theory of cancer-toxin pathogenesis, this article proposes that cancer toxin persists throughout the entire course of colorectal cancer(CRC), with spleen qi depletion as the root of disease and damp-heat and stasis toxin as key factors in the evolution of pathogenesis. It further explores the intrinsic relationship between these pathogenetic features and the modern pathological process of "inflammasome pre-activation/repeated activation/gasdermin D-mediated pyroptotic microenvironmental imbalance". Spleen qi depletion is regarded as an upstream pathological basis for inflammasome pre-activation, while damp-heat and stasis toxin are considered key drivers of repeated inflammasome activation, the gasdermin D-mediated amplification of pyroptotic inflammation, and persistent microenvironmental imbalance. These two pathogenetic aspects interact sequentially and concurrently, jointly contributing to the early development and progression of CRC. Guided by the principle of anti-cancer and detoxification, and based on the traditional Chinese medicine(TCM) treatment strategy of simultaneously fortifying the spleen and replenishing qi, clearing and resolving damp-heat, and resolving stasis and toxins, this study further elucidates the modern mechanistic connotations of how these relevant therapies intervene in the gasdermin D-mediated pyroptotic microenvironment imbalance in CRC. The ultimate aim is to provide a theoretical basis for the modern scientific interpretation of cancer-toxin pathogenesis and the clinical syndrome differentiation and treatment of CRC.

参考文献

[1]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3):229-263.

[2]Dong X, Yang J, He L, et al. The barrier-microbiotainflammation axis in colorectal cancer:mechanisms and emerging diagnostic&therapeutic strategies[J]. Cancers(Basel), 2026, 18(4):576-601.

[3]Neurath M F, Artis D, Becker C. The intestinal barrier:a pivotal role in health, inflammation, and cancer[J]. Lancet Gastroenterol Hepatol, 2025, 10(6):573-592.

[4]Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575):660-665.

[5]Chen J, Singh N, Ye X, et al. Gut microbiota-mediated activation of GSDMD ignites colorectal tumorigenesis[J].Cancer Gene Ther, 2024, 31(7):1007-1017.

[6]程海波,李柳,吴勉华,等.癌毒病机理论辨治肠癌探讨[J].时珍国医国药,2017, 28(10):2487-2488.

[7]魏小曼,李柳,程海波.结直肠癌前病变中医病机探讨[J].南京中医药大学学报,2021, 37(3):348-351.

[8]Li Q, Von Ehrlich-Treuenstätt V, Schardey J, et al. Gut barrier dysfunction and bacterial lipopolysaccharides in colorectal cancer[J]. J Gastrointest Surg, 2023, 27(7):1466-1472.

[9]Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome:an overview of mechanisms of activation and regulation[J/OL]. Int J Mol Sci, 2019, 20(13):3328.https://pubmed. ncbi. nlm. nih. gov/31284572/.

[10]Cheng C K, Yi M, Wang L, et al. Role of gasdermin D in inflammatory diseases:from mechanism to therapeutics[J/OL]. Front Immunol, 2024, 15:1456244. https://pubmed. ncbi. nlm. nih. gov/39253076/.

[11]程海波,李柳,沈卫星,等.癌毒病机辨治体系的构建[J].南京中医药大学学报,2022, 38(7):559-564.

[12]程海波.癌毒病机理论探讨[J].中医杂志,2014, 55(20):1711-1715.

[13]李仪琳,姬航宇,张润顺,等.基于脾胃气化内涵探讨中医药对肠黏膜屏障的保护作用[J].中国中西医结合消化杂志,2023, 31(10):816-820.

[14]王皓月,高嘉敏,陈鑫,等.范忠泽基于“脾为之卫”理论防治结直肠癌的机理与策略[J].中医药导报,2025, 31(5):195-199.

[15]程海波,李柳,周学平,等.中医肿瘤癌毒病机辨证体系的创建[J].中医杂志,2020, 61(20):1767-1770.

[16]Bauernfeind F G, Horvath G, Stutz A, et al. Cutting edge:NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009,183(2):787-791.

[17]李柳,程海波,叶放,等.从病机辨证探析国医大师周仲瑛复法组方辨治肿瘤的经验[J].南京中医药大学学报,2021, 37(5):765-768.

[18]姚望,唐宇飞,石齐,等.基于阴阳理论探讨中医药调节活性氧在恶性肿瘤防治中的作用[J].上海中医药杂志,2025, 59(6):42-47.

[19]Harijith A, Ebenezer D L, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation[J/OL]. Front Physiol, 2014, 5:352. https://pubmed. ncbi. nlm. nih. gov/25324778/.

[20]周利红,王婷,韩植芬,等.大肠癌血瘀证与非血瘀证患者肿瘤组织血管新生标记物、HIF-1α和VEGF表达的差异性[J].上海中医药杂志,2019, 53(10):28-32.

[21]朱紫妍,朱芸萱,陈琼,等.活血化瘀药影响肿瘤转移的分子机制研究进展[J].南京中医药大学学报,2025,41(9):1251-1257.

[22]Martin J D, Seano G, Jain R K. Normalizing function of tumor vessels:progress, opportunities, and challenges[J/OL]. Annu Rev Physiol, 2019, 81:505-534. https://pubmed. ncbi. nlm. nih. gov/30742782/.

[23]Corcoran S E, O'Neill L A J. HIF1α and metabolic reprogramming in inflammation[J]. J Clin Invest, 2016,126(10):3699-3707.

[24]Tannahill G M, Curtis A M, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α[J]. Nature, 2013, 496(7444):238-242.

[25]程海波,王俊壹,李柳.癌毒病机分类及其在肿瘤临床治疗中的应用[J].中医杂志,2019, 60(2):119-122.

[26]程海波,李柳,孙东东,等.抗癌解毒法的建立与应用[J].中医杂志,2022, 63(15):1420-1426.

[27]任明名,顾立梅,杨文娟,等.国医大师周仲瑛从湿热瘀毒、脾气亏虚论治结直肠癌经验[J].中华中医药杂志,2022, 37(8):4488-4492.

[28]王俊壹,李柳,程海波.仙连解毒方联合XELOX方案治疗Ⅳ期结直肠癌的临床研究[J].中医药学报,2022,50(2):77-81.

[29]Gao Y J, Wu X P, Ye B B, et al. Liu-jun-zi decoction alleviates chemotherapy-induced anorexia by regulating gut microbiota and TLR4/MyD88/NF-κB p65 signaling pathway[J/OL]. Tradit Med Res, 2024, 9(8):47.https://www. tmrjournals. com/public/article PDF/20240409/e18ef46bc85b62a576016aae7dffa764. pdf.

[30]张兆鹏,李秋英,于子晴,等.柴芍六君子汤通过TLR4/MyD88/NF-κB信号通路抗溃疡性结肠炎的机制[J].中国实验方剂学杂志,2022,28(19):17-23.

[31]张远哲,黎豫川,杨元凤,等.香砂六君子汤对脾虚型IBS-D大鼠肠道菌群及其代谢产物SCFAs的调节作用[J].中成药,2024, 46(1):272-277.

[32]Cai K, Cao X Y, Chen F, et al. Xianlian jiedu decoction alleviates colorectal cancer by regulating metabolic profiles, intestinal microbiota and metabolites[J/OL].Phytomedicine, 2024, 128:155385. https://pubmed.ncbi. nlm. nih. gov/38569292/.

[33]Luo J W, Xu W C, Yan Q Y, et al. Mechanistic analysis of Xianlian Jiedu Decoction in inflammation-associated colorectal carcinogenesis based on transcriptomics and network pharmacology[J]. J Nanjing Univ Tradit Chin Med, 2026, 42(3):365-375.

基本信息:

DOI:10.13288/j.11-2166/r.2026.19.006

中图分类号:R273

引用信息:

[1]许戈辉,孙晓荷,李柳,等.癌毒病机理论视角下结直肠癌消皮素D介导焦亡微环境失衡的病机阐释及辨治思路[J].中医杂志,2026,67(19):2063-2067.DOI:10.13288/j.11-2166/r.2026.19.006.

基金信息:

国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202208);国家中医药管理局高水平中医药重点学科建设项目(国中医药人教函[2023]85号); 江苏省教育厅江苏高校优势学科建设工程项目

发布时间:

2026-09-29

出版时间:

2026-09-29

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文